What Vyvgart Hytrulo treats
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) is a subcutaneous formulation of Vyvgart, approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor (AChR) antibody positive. It offers the same proven benefits as intravenous Vyvgart, with the added convenience of a subcutaneous injection administered in minutes.
Benefits of Vyvgart Hytrulo
Patients using Vyvgart Hytrulo may experience:
- Rapid reduction in muscle weakness
- Improved mobility, breathing, swallowing, and quality of life
- Convenient subcutaneous dosing with no need for IV access
- Flexible administration in outpatient or home settings
With its short administration time, Vyvgart Hytrulo enhances patient comfort and accessibility while maintaining the efficacy of the original IV formulation.
Possible Side Effects of Vyvgart Hytrulo
Vyvgart Hytrulo is generally well-tolerated. Common side effects may include:
- Injection site reactions (pain, redness, or bruising)
- Headache
- Respiratory tract or urinary infections
- Fatigue
Serious side effects are rare but may include:
- Increased risk of infections due to lower IgG levels
- Hypersensitivity reactions
Patients should be monitored for signs of infection and report any unusual symptoms to their healthcare provider.
How infusion works at Prime
Vyvgart Hytrulo is administered at our infusion centers across New York and Atlanta. Our dedicated care team coordinates every step of your treatment with your prescribing physician.
Getting started
Patients: if you have a referral for Vyvgart Hytrulo, send us an inquiry using the form below and our care team will take it from there. Physicians: referring a patient to Prime Infusions is simple — just complete and fax or email the referral form above.
Ready to start?
For a medical emergency, call 911.
Our Infusion Centers
FAQ
Frequently asked questions
How Does Vyvgart Hytrulo Work?
Vyvgart Hytrulo combines efgartigimod alfa—an FcRn blocker—with hyaluronidase, which enhances absorption of the drug under the skin. The medication reduces levels of IgG autoantibodies by blocking the neonatal Fc receptor (FcRn), a protein that normally protects IgG from degradation. In gMG, harmful IgG antibodies disrupt nerve-to-muscle communication. By accelerating their breakdown, Vyvgart Hytrulo helps relieve muscle weakness and improve neuromuscular function. It is administered via subcutaneous injection once weekly for four weeks, with additional cycles based on patient response.
Who is Vyvgart Hytrulo For?
Vyvgart Hytrulo is indicated for adults with generalized myasthenia gravis who are anti-AChR antibody positive. It is an ideal option for patients who:
- Prefer a subcutaneous alternative to IV infusions
- Require flexible administration outside of an infusion center
- Are seeking fast-acting, targeted relief from gMG symptoms